Reata Pharmaceuticals Prices Upsized 2.4M Share Class A Common Stock Public Offering @$183/Share

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) any") announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the origi

Benzinga · 11/14/2019 09:08

Reata Pharmaceuticals, Inc. (NASDAQ: RETA) any") announced the pricing of an underwritten public offering of 2,400,000 shares of its Class A common stock at a price to the public of $183.00 per share. The offering was upsized to 2,400,000 shares from the original offering size of 2,000,000 shares. The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $439,200,000. The offering is expected to close on November 18, 2019, subject to customary closing conditions. In addition, Reata has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of Reata's Class A common stock on the same terms and conditions.

Citigroup, Jefferies, SVB Leerink and Stifel are acting as the joint book-running managers for the offering. Baird, Cantor and Ladenburg Thalmann are acting as co-managers for the offering.

Reata intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file New Drug Applications for bardoxolone for the treatment of patients with Alport syndrome and omaveloxolone for the treatment of patients with Friedreich's ataxia, planning for commercialization of its potential products, and making payments due under its agreement with AbbVie Inc.